NewTimeSpace News:On March 12, 2026, UltraGreen.ai, a global provider of fluorescence-guided surgery and digital health solutions, announced that its handheld near-infrared fluorescence imaging system, IC-FlowTM Imaging System V2, has successfully obtained regulatory approvals in four countries: India, Thailand, the Philippines and Bangladesh.

According to the announcement, the approval in India was granted by the Central Drugs Standard Control Organisation (CDSCO) of the Government of India; in Thailand, by the Thai Medical Device Control Division; in the Philippines, by the Centre for Device Regulation, Health and Research (CDRRHR); and in Bangladesh, by the Directorate General of Drug Administration (DGDA). Following these approvals, UltraGreen.ai is authorized to commercially launch the imaging system in the aforementioned four countries in compliance with local regulatory requirements, expanding its global regulatory approval footprint to 45 territories.

It is reported that the IC-FlowTM Imaging System V2, a core fluorescence imaging product of the company, is primarily used for intraoperative visualization in open surgical procedures. It can assess tissue perfusion and flap circulation in plastic and micro-reconstructive surgery, support organ transplant procedures, and enable the visualization of lymphatic flow.

Declan Cassells, Chief Operating Officer of UltraGreen.ai, stated that this series of regulatory approvals reflects the company's ongoing commitment to promoting compliant fluorescence imaging technologies in the region. It will facilitate the company's collaboration with local healthcare institutions, distributors and clinical partners, while strictly adhering to local regulatory frameworks.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.